Cromoglicic acid
Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate (former BAN), or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
License data | |
Pregnancy category |
|
Routes of administration | topical: oral, nasal spray, inhaled, eye drops |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 1% |
Elimination half-life | 1.3 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.036.602 |
Chemical and physical data | |
Formula | C23H16O11 |
Molar mass | 468.370 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Cromoglicic acid has been the non-corticosteroid treatment of choice in the treatment of asthma, for which it has largely been replaced by leukotriene receptor antagonists because of their convenience (and perceived safety). Cromoglicic acid requires administration four times daily, and does not provide additive benefit in combination with inhaled corticosteroids.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.